Advanced Hyaluronic Acid Technologies
Studio Bioscience is advancing ARC, a proprietary hyaluronic acid platform designed to support differentiated intra-articular HA injectable products for joint health, osteoarthritis, and related orthopedic applications.
Led by Dr. Polyak, Studio Bioscience combines deep HA formulation expertise with patented and patent-pending technologies across joint, aesthetic, and ophthalmic applications.
ARC is Studio Bioscience’s proprietary hyaluronic acid technology platform.
The platform is designed to support controlled HA structuring and application-specific formulation development.
ARC may enable partners to develop differentiated HA-based products with tailored rheological, structural, and functional properties.
Potential applications include:
Dr. Polyak has extensive experience developing HA-based technologies across aesthetic, ophthalmic, medical device, and injectable applications.
His work includes HA-based aesthetic injectable technologies licensed for selected markets, as well as HA-based ophthalmic formulation development for a partner company.
This track record supports Studio Bioscience’s ability to adapt HA expertise across multiple biomedical use cases and collaborate with partners from formulation development through commercialization-oriented programs.
HA-based aesthetic injectable technologies have been licensed for the United States and Latin America. Geographic rights for Europe and Canada remain available, subject to existing agreements and field restrictions.
Dr. Polyak has contributed to HA-based ophthalmic formulation development for a partner company. Studio Bioscience is interested in identifying North American GMP manufacturing partners for HA-based ophthalmic products.
Studio Bioscience is actively engaging qualified partners for licensing, co-development, and manufacturing discussions.